Three-Month Treatment With a Long-Acting Gonadotropin-Releasing Hormone Agonist of Patients With Benign Prostatic Hyperplasia: Effects on Tissue Androgen Concentration, 5α-Reductase Activity and Androgen Receptor Content
February 1989
in “
The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism
”
gonadotropin-releasing hormone agonist benign prostatic hyperplasia testosterone dihydrotestosterone 5α-androstan-3α,17β-diol 5α-reductase androgen receptor cytosolic androgen receptor nuclear androgen receptor plasma testosterone GnRH agonist BPH T DHT 3α-diol 5α-reductase AR cytosolic AR nuclear AR plasma T
Studysummary This study found that in men with benign prostatic hyperplasia, a 3-month treatment with a long-acting GnRH agonist significantly reduced intraprostatic DHT and 3α-diol levels by about 90% and testosterone by about 75%.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on academic.oup.com →